Human B7-2 / CD86 Protein, His Tag (MALS verified)
分子別名(Synonym)
CD86,B7-2,B70,CD28LG2,LAB72,MGC34413
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Human B7-2, His Tag (CD6-H5223) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).
Predicted N-terminus: Leu 26
蛋白結(jié)構(gòu)(Molecular Characterization)

This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.2 kDa. The protein migrates as 40-63 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method / rFC method.
純度(Purity)
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.


背景介紹
分化簇86(CD86)亦稱B淋巴細(xì)胞激活抗原B7-2,是一種屬于免疫球蛋白超家族的I型膜蛋白。該蛋白組成性表達(dá)于并指樹(shù)突狀細(xì)胞、朗格漢斯細(xì)胞、外周血樹(shù)突狀細(xì)胞、記憶B細(xì)胞及生發(fā)中心B細(xì)胞表面,同時(shí)在單核細(xì)胞中呈低水平表達(dá),并可經(jīng)γ干擾素誘導(dǎo)上調(diào)。CD86是T細(xì)胞表面兩種不同蛋白的配體:CD28(參與自身調(diào)節(jié)與細(xì)胞間聯(lián)結(jié))和CTLA-4(參與調(diào)節(jié)衰減與細(xì)胞解離)。CD86與CD80協(xié)同作用啟動(dòng)T細(xì)胞。最新研究表明,B7-2能促進(jìn)成熟抗原呈遞細(xì)胞(APC)譜系的形成,并增強(qiáng)APC功能與存活能力。此外,B7蛋白家族還通過(guò)激活巨噬細(xì)胞中的NF-κB信號(hào)通路參與先天免疫應(yīng)答。因此,CD86被視為免疫治療的重要靶點(diǎn)。在霍奇金淋巴瘤患者中,CD86陽(yáng)性巨噬細(xì)胞是預(yù)測(cè)一線療法潛在無(wú)效的獨(dú)立標(biāo)志物。
關(guān)鍵字: B7-2;B7-2蛋白;B7-2重組蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。